Latest Hotspot

EMA Reviews GSK's Arexvy RSV Vaccine for Adults 50-59 at High Infection Risk

7 February 2024
3 min read

British pharmaceutical giant GSK plc has disclosed that its submission for authorization expansion concerning its novel adjuvanted recombinant vaccine to combat respiratory syncytial virus has been formally accepted by the European Medicines Agency. The aim is to broaden its application to encompass individuals in the 50 to 59 age group who have a heightened susceptibility to RSV infections. Should the approval be granted, this groundbreaking vaccine by GSK would stand as a pioneering preventive measure for this specific demographic.

👇Explore more about this drug by clicking the image below. Gain detailed insights into its R&D Status, Core Patent, Clinical Trials and Global Approval Status. Stay informed and updated.图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

In the European market, Arexvy has received approval for preventing RSV-induced lower respiratory tract illnesses among individuals aged 60 and up. Research indicates that individuals in their fifties who are more susceptible to RSV have a similar level of risk as those aged 60 and older.

The submission for regulatory approval is a direct consequence of encouraging findings from a phase III clinical study which examined the immunogenicity and safety profile of the RSV disease

 vaccine developed by GSK. This trial included participants in their fifties who faced a heightened threat of contracting RSV-LRTD, particularly due to pre-existing health concerns.

The true extent of RSV's impact on adults could be greater than currently acknowledged. This is partly because of a general lack of recognition of the disease, nonuniform diagnostic practices, and gaps in the data collection of surveillance research. Individuals suffering from health issues such as COPD, asthma, chronic heart disease, and diabetes are particularly vulnerable to RSV-related complications. In these cases, RSV can worsen the primary condition, potentially leading to severe pneumonia, hospital admissions, or even mortality.

GSK stands at the forefront among pharmaceutical firms, having submitted a request to regulatory authorities to permit the use of the RSV vaccine in adults between 50 and 59 years of age who have pre-existing medical conditions that increase their risk of RSV infection. A decision from European regulators about this application is expected to arrive in the second half of 2024.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this indications in just a click!图形用户界面, 文本, 应用程序, 电子邮件, 网站

描述已自动生成

According to the data provided by the Synapse Database, As of February 6, 2024, there are 227 investigational drugs for the Respiratory Syncytial Virus Infections, including 32 targets, 189 R&D institutions involved, with related clinical trials reaching 569, and as many as 5715 patents.

the Respiratory Syncytial Virus Vaccine developed by GSK Plc is a prophylactic vaccine aimed at preventing RSV infections. It has received regulatory approval in the United States and is currently in the IND approval stage in China. The vaccine has reached the highest phase of development globally and has been granted Priority Review status, highlighting its potential to address a significant medical need.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Making the Most Out of Synapse: Searching for Baclofen
Drug Insights
2 min read
Making the Most Out of Synapse: Searching for Baclofen
7 February 2024
Baclofen, sold under the brand name Lioresal among others, is a medication used to treat muscle spasticity such as from a spinal cord injury or multiple sclerosis.
Read →
EU Commission clears GSK's drug Omjjara (momelotinib) for use
Latest Hotspot
4 min read
EU Commission clears GSK's drug Omjjara (momelotinib) for use
6 February 2024
GSK plc announced the European Commission's approval of Omjjara (momelotinib) for market launch. This daily oral drug inhibits both JAK1/JAK2 and activin A receptor type 1.
Read →
Synapse Simplified: How to Find Ciprofloxacin Information
Drug Insights
2 min read
Synapse Simplified: How to Find Ciprofloxacin Information
6 February 2024
Ciprofloxacin is a fluoroquinolone antibiotic used to treat a number of bacterial infections. It can be taken by mouth, as eye drops, as ear drops, or intravenously.
Read →
Alvotech Reveals Promising Preliminary Results for Potential Prolia® and Xgeva® Equivalent, AVT03
Latest Hotspot
2 min read
Alvotech Reveals Promising Preliminary Results for Potential Prolia® and Xgeva® Equivalent, AVT03
6 February 2024
Alvotech Reveals Encouraging Preliminary Findings from Drug Behavior Analysis of AVT03, a Potential Equivalent to Prolia® and Xgeva®.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.